دورية أكاديمية

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

التفاصيل البيبلوغرافية
العنوان: Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India
المؤلفون: Rekha Vijay Kumar, Dipti Panwar, Usha Amirtham, Chennagiri Srinivasmurthy Premalata, Champaka Gopal, Suma Mysore Narayana, Geetha Vikram Patil Okaly, K C Lakshmaiah, S Krishnamurthy
المصدر: South Asian Journal of Cancer, Vol 7, Iss 1, Pp 7-10 (2018)
بيانات النشر: Thieme Medical and Scientific Publishers Pvt. Ltd., 2018.
سنة النشر: 2018
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Breast cancer, human epidermal growth factor receptor-2, hormone receptor, immunohistochemistry, triple-negative breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Aim: The aim of the study was to analyze the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status over 7 years in South Indian women with breast cancer. Further analysis of a subgroup was done to study clinically defined subtypes and the role of preanalytical factors in needle core biopsies (NCBs) and excised specimens. Materials and Methods: This was a retrospective study from January 2010 to December 2016. Patients diagnosed with invasive breast cancer and available immunohistochemistry (IHC) reports of ER, PR, and HER2 status were analyzed. The cases for the year 2016 were analyzed further to observe the impact of preanalytical factors on the IHC staining patterns and surrogate status. Results: A total of 5436 patients were included with a median age of 48 years. Among these, 65% were ≤ 55 years. The overall incidence of hormone receptor (HR)-positive patients was 48%; HER2 positive, 15%; and triple-negative breast cancer (TNBC), 37%. The incidence of HR positive, HER2 positive, and TNBC were 45%, 16%, and 39% and 53%, 13%, and 34% in patients
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2278-330X
Relation: http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=1;spage=7;epage=10;aulast=Kumar; https://doaj.org/toc/2278-330X
DOI: 10.4103/sajc.sajc_211_17
URL الوصول: https://doaj.org/article/a96f93073e65429fb75f76e87843516e
رقم الأكسشن: edsdoj.96f93073e65429fb75f76e87843516e
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2278330X
DOI:10.4103/sajc.sajc_211_17